Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide
暂无分享,去创建一个
Denis Guilloteau | Sylvie Chalon | D. Guilloteau | S. Chalon | J. Besnard | Marie-Claire Venier-Julienne | M. Venier-Julienne | Christelle Gouhier | Sylvie Bodard | Jean-Pierre Benoit | Jean-Claude Besnard | S. Bodard | Jean-Pierre Benoit | C. Gouhier
[1] D. Schober,et al. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[2] M. Peschanski,et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease , 1997, Nature.
[3] E. Mufson,et al. TrkA‐immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin , 1994, The Journal of comparative neurology.
[4] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[5] F. Hefti,et al. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA , 1994, Neuroscience.
[6] D. Guilloteau,et al. Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: iodobenzamide and iodoethylspiperone. , 1993, Life sciences.
[7] B. Bloch,et al. D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum , 1990, Neuroscience Letters.
[8] Joseph B. Martin,et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.
[9] S. W. Davies,et al. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones , 1992, Neuroscience Letters.
[10] B. Hyman,et al. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids , 1991, Neuroscience.
[11] H Toyama,et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[13] Marc Laruelle,et al. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.
[14] I. Ferrer,et al. TrkA immunoreactivity in reactive astrocytes in human neurodegenerative diseases and colchicine-treated rats , 1998, Acta Neuropathologica.
[15] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[16] J. Roder,et al. Localization of CNTF immunoreactivity to neurons and astroglia in the CNS. , 1994, Brain research. Molecular brain research.
[17] P. Brachet,et al. Intracerebral Implantation of NGF-Releasing Biodegradable Microspheres Protects Striatum against Excitotoxic Damage , 2000, Experimental Neurology.